Alexa Victoria Patton, AUD | |
1492 S Mill Ave Ste 301, Tempe, AZ 85281-5676 | |
(480) 894-5550 | |
Not Available |
Full Name | Alexa Victoria Patton |
---|---|
Gender | Female |
Speciality | |
Experience | Years |
Location | 1492 S Mill Ave Ste 301, Tempe, Arizona |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1164089546 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
231H00000X | Audiologist | DA11786 (Arizona) | Secondary |
237600000X | Audiologist-hearing Aid Fitter | DA11786 (Arizona) | Primary |
Mailing Address | Practice Location Address |
---|---|
Alexa Victoria Patton, AUD 1010 E Mcdowell Rd Ste Ll1, Phoenix, AZ 85006-2606 Ph: (602) 956-1250 | Alexa Victoria Patton, AUD 1492 S Mill Ave Ste 301, Tempe, AZ 85281-5676 Ph: (480) 894-5550 |
News Archive
Non-Hispanic Black individuals in four U.S. states experienced a 38% increase in the rate of opioid overdose deaths from 2018 to 2019, while the rates for other race and ethnicity groups held steady or decreased, according to a new study by the National Institutes of Health published in the American Journal of Public Health.
GLP-1 is a hormone that regulates glucose levels in the body by stimulating the secretion of insulin, and GLP-1 also inhibits appetite. "We have found that GLP-1 is reduced by up to 25% among people with pre-diabetes and up to 20% among obese people compared to normal weight people.
Individuals with diabetes who adhere to their medication had lower risk of hospitalization by one-third when compared to patients who do not adhere to their medication, according to a new study. The results of the study by Prime Therapeutics (Prime), a thought leader in pharmacy benefit management, are being presented the last week in April at the Academy of Managed Care Pharmacy's 23rd Annual Meeting and Showcase in Minneapolis, Minn.
Meda announced today that the European Commission (EC) has granted marketing authorization for Zyclara in the European Union. Zyclara (imiquimod 3.75% cream) is a patented product for the treatment of actinic keratosis.
› Verified 1 days ago